Cyclin i promotes cisplatin resistance via Cdk5 activation in cervical cancer

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 23, 2015, Pages 4533-4541

  Li, R ^a   Liu, G Z ^a   Luo, S Y ^a   Chen, R ^a   Zhang, J X ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Cdk5; Cervical cancer; Cisplatin resistance; Cyclin I

Indexed keywords

BETA ACTIN; CISPLATIN; CYCLIN DEPENDENT KINASE 5; CYCLIN I; MESSENGER RNA; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CDK5 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; GENE SILENCING; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERIAL ANALYSIS OF GENE EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; UTERINE CERVICAL NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; CYCLIN I; CYCLIN-DEPENDENT KINASE 5; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; RNA, SMALL INTERFERING; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84966319174     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. SIEGEL R, NAISHADHAM D, JEMAL A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. MANCUSO S, SMANIOTTO D, BENEDETTI PANICI P, FAVALE B, GREGGI S, MANFREDI R, MARGARITI PA, MORGANTI AG, SCAMBIA G, TORTORETO F, VALENTINI V, CELLINI N. Phase I-II trial of preoperative chemoradiation in locally advanced cervical carcinoma. Gynecol Oncol 2000; 78(3 Pt 1): 324-328.
3. THOMAS GM. Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy. N Engl J Med 1999; 340: 1198-1200.
4. IM SS, MONK BJ. New developments in the treatment of invasive cervical cancer. Obstet Gynecol Clin North Am 2002; 29: 659-672.
5. BONOMI P, BLESSING JA, STEHMAN FB, DISAIA PJ, WALTON L, MAJOR FJ. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a gynecologic Oncology Group study. J Clin Oncol 1985; 3: 1079-1085.
6. EVANS T, ROSENTHAL ET, YOUNGBLOM J, DISTEL D, HUNT T. Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 1983; 33: 389-396.
7. NAKAMURA T, SANOKAWA R, SASAKI YF, AYUSAWA D, OISHI M, MORI N. Cyclin I: a new cyclin encoded by a gene isolated from human brain. Exp Cell Res 1995; 221: 534-542.
8. JENSEN MR, AUDOLFSSON T, FACTOR VM, THORGEIRSSON SS. In vivo expression and genomic organization of the mouse cyclin I gene (Ccni). Gene 2000; 256: 59-67.
9. SHERMAN-BAUST CA, WEERARATNA AT, RANGEL LB, PIZER ES, CHO KR, SCHWARTZ DR, SHOCK T, MORIN PJ. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 2003; 3: 377-386.
10. MALMBERG J, TOLMACHEV V, ORLOVA A. Imaging agents for in vivo molecular profiling of disseminated prostate cancer: cellular processing of [(111)In]-labeled CHX-A''DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines. Exp Ther Med 2011; 2: 523-528.
11. BRINKKOETTER PT, OLIVIER P, WU JS, HENDERSON S, KROFFT RD, PIPPIN JW, HOCKENBERY D, ROBERTS JM, SHANKLAND SJ. Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cells. J Clin Invest 2009; 119: 3089-3101.
12. MANDIC A, HANSSON J, LINDER S, SHOSHAN MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003; 278: 9100-9106.
13. ROBATI M, HOLTZ D, DUNTON CJ. A review of topotecan in combination chemotherapy for advanced cervical cancer. Ther Clin Risk Manag 2008; 4: 213-218.
14. KOBERLE B, TOMICIC MT, USANOVA S, KAINA B. Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 2010; 1806: 172-182.
15. SELVENDIRAN K, AHMED S, DAYTON A, KUPPUSAMY ML, RIVERA BK, KALAI T, HIDEG K, KUPPUSAMY P. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Cancer Biol Ther 2011; 12: 837-845.
16. CASTAGNA A, ANTONIOLI P, ASTNER H, HAMDAN M, RIGHETTI SC, PEREGO P, ZUNINO F, RIGHETTI PG. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 2004; 4: 3246-3267.
17. YEH PY, CHUANG SE, YEH KH, SONG YC, EA CK, CHENG AL. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem Pharmacol 2002; 63: 1423-1430.
18. BRITTEN RA, LIU D, TESSIER A, HUTCHISON MJ, MURRAY D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 2000; 89: 453-457.
19. CYBULSKI M, JAROSZ B, NOWAKOWSKI A, JELENIEWICZ W, SEROCZYNSKI P, MAZUREK-KOCIUBOWSKA M. Cyclin I correlates with VEGFR-2 and cell proliferation in human epithelial ovarian cancer. Gynecol Oncol 2012; 127: 217-222.
20. LANDBERG G, NILSSON K, JIRSTROM K, RYDEN L, KITCHING R, BURGER AM, SETH A. Cyclin I is expressed in human breast cancer and closely associated with VEGF and KDR expression. Breast Cancer Res Treat 2005; 89: 313-316.
21. GRIFFIN SV, OLIVIER JP, PIPPIN JW, ROBERTS JM, Shankland SJ. Cyclin I protects podocytes from apoptosis. J Biol Chem 2006; 281: 28048-28057.
22. BRINKKOETTER PT, WU JS, OHSE T, KROFFT RD, SCHERMER B, BENZING T, PIPPIN JW, SHANKLAND SJ. p35, the non-cyclin activator of Cdk5, protects podocytes against apoptosis in vitro and in vivo. Kidney Int 2010; 77: 690-699.
23. SETH A, KITCHING R, LANDBERG G, XU J, ZUBOVITS J, BURGER AM. Gene expression profiling of ductal carcinomas in situ and invasive breast tumors. Anticancer Res 2003; 23: 2043-2051.
24. DEMETRICK DJ, ZHANG H, BEACH DH. Chromosomal mapping of human CDK2, CDK4, and CDK5 cell cycle kinase genes. Cytogenet Cell Genet 1994; 66:72-74.
25. DHAVAN R AND TSAI LH. A decade of CDK5. Nature reviews Mol Cell Biol 2001; 2: 749-759.
26. SHETTY KT, KAECH S, LINK WT, JAFFE H, FLORES CM, WRAY S, PANT HC, BEUSHAUSEN S. Molecular characterization of a neuronal-specific protein that stimulates the activity of Cdk5. J Neurochem 1995; 64: 1988-1995.
27. LIN H, JUANG JL, WANG PS. Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis. J Biol Chem 2004; 279: 29302-29307.
28. WEISHAUPT JH, NEUSCH C, BAHR M. Cyclin-dependent kinase 5 (CDK5) and neuronal cell death. Cell Tissue Res 2003; 312: 1-8.